Tango Therapeutics(TNGX)
$21.89-0.22 (-1.00%)
TNGX
Tango Therapeutics financials statements
$21.89
At close:-0.22 (-1.00%)
Want to see TNGX full AI Analyst Report?
Tango Therapeutics (TNGX) Ratios
546 Followers
Tango Therapeutics Ratios
TNGX's free cash flow for Q3 2026 was $-37.22M. For the 2026 fiscal year, TNGX's free cash flow was decreased by $-77.00K and operating cash flow was $-37.14M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 16.32 | 6.98 | 7.54 | 6.76 | 12.10 |
| Quick Ratio | 16.32 | 6.98 | 7.54 | 6.76 | 12.10 |
| Cash Ratio | 5.18 | 1.82 | 1.45 | 1.08 | 3.51 |
| Solvency Ratio | -1.89 | -1.09 | -0.66 | -0.57 | -0.37 |
| Operating Cash Flow Ratio | -6.41 | -3.45 | -2.57 | -1.96 | -1.46 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 301.25M | $ 149.37M | $ 197.08M | $ 188.28M | $ 336.93M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.12 | 0.10 | 0.09 | 0.00 |
| Debt-to-Equity Ratio | 0.10 | 0.18 | 0.15 | 0.16 | 0.00 |
| Debt-to-Capital Ratio | 0.09 | 0.15 | 0.13 | 0.14 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.15 | 1.59 | 1.59 | 1.75 | 1.45 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.29 | 0.33 | 0.41 | 0.47 | 0.02 |
| Net Debt to EBITDA | 0.79 | 0.26 | 0.25 | 0.17 | 2.47 |
| Profitability Margins | |||||
| Gross Profit Margin | 96.34% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -162.85% | -309.24% | -312.57% | -446.79% | -157.09% |
| EBITDA Margin | -159.19% | -303.30% | -305.96% | -440.32% | -154.67% |
| Operating Profit Margin | -178.39% | -346.09% | -312.57% | -446.79% | -157.09% |
| Pretax Profit Margin | -162.85% | -309.24% | -278.18% | -434.92% | -156.43% |
| Net Profit Margin | -162.85% | -309.73% | -278.54% | -435.14% | -157.21% |
| Continuous Operations Profit Margin | -162.85% | -309.73% | -278.54% | -435.14% | -157.21% |
| Net Income Per EBT | 100.00% | 100.16% | 100.13% | 100.05% | 100.50% |
| EBT Per EBIT | 91.28% | 89.35% | 89.00% | 97.34% | 99.58% |
| Return on Assets (ROA) | -25.48% | -41.17% | -25.27% | -24.78% | -11.64% |
| Return on Equity (ROE) | -29.35% | -65.31% | -40.20% | -43.36% | -16.89% |
| Return on Capital Employed (ROCE) | -29.52% | -52.31% | -32.01% | -29.16% | -12.66% |
| Return on Invested Capital (ROIC) | -29.31% | -51.85% | -31.83% | -29.02% | -12.62% |
| Return on Tangible Assets | -25.48% | -41.17% | -25.27% | -24.78% | -11.64% |
| Earnings Yield | -9.87% | -38.61% | -10.87% | -16.99% | -8.57% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 12.43 | 18.52 |
| Payables Turnover | 1.93 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 1.47 | 0.88 | 0.68 | 0.43 | 6.09 |
| Asset Turnover | 0.16 | 0.13 | 0.09 | 0.06 | 0.07 |
| Working Capital Turnover Ratio | 0.22 | 0.16 | 0.12 | 0.06 | 0.12 |
| Cash Conversion Cycle | -189.14 | 0.00 | 0.00 | 29.36 | 19.71 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 29.36 | 19.71 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 189.14 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 29.36 | 19.71 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.20 | -1.20 | -1.25 | -1.24 | -0.96 |
| Free Cash Flow Per Share | -1.20 | -1.21 | -1.26 | -1.33 | -0.99 |
| Dividend Paid and CapEx Coverage Ratio | -132.52 | -174.40 | -77.31 | -14.18 | -32.40 |
| Capital Expenditure Coverage Ratio | -132.52 | -174.40 | -77.31 | -14.18 | -32.40 |
| Operating Cash Flow Coverage Ratio | -4.14 | -3.60 | -3.03 | -2.65 | -39.61 |
| Operating Cash Flow to Sales Ratio | -2.23 | -3.13 | -3.23 | -4.39 | -1.61 |
| Free Cash Flow Yield | -13.60% | -39.19% | -12.76% | -18.34% | -9.03% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -10.18 | -2.60 | -9.20 | -5.89 | -11.67 |
| Price-to-Sales (P/S) Ratio | 16.50 | 8.02 | 25.63 | 25.61 | 18.34 |
| Price-to-Book (P/B) Ratio | 2.97 | 1.69 | 3.70 | 2.55 | 1.97 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.36 | -2.55 | -7.83 | -5.45 | -11.07 |
| Price-to-Operating Cash Flow Ratio | -7.41 | -2.57 | -7.94 | -5.84 | -11.41 |
| Price-to-Earnings Growth (PEG) Ratio | 0.38 | -0.25 | 0.75 | -0.19 | 0.28 |
| Enterprise Value Multiple | -9.57 | -2.39 | -8.13 | -5.64 | -9.39 |
| Enterprise Value | 950.52M | 304.47M | 908.80M | 617.86M | 538.22M |
| EV to EBITDA | -9.57 | -2.39 | -8.13 | -5.64 | -9.39 |
| EV to Sales | 15.24 | 7.24 | 24.88 | 24.85 | 14.53 |
| EV to Free Cash Flow | -6.79 | -2.30 | -7.60 | -5.29 | -8.77 |
| EV to Operating Cash Flow | -6.84 | -2.32 | -7.70 | -5.66 | -9.04 |
| Tangible Book Value Per Share | 2.98 | 1.83 | 2.68 | 2.84 | 5.55 |
| Shareholders’ Equity Per Share | 2.98 | 1.83 | 2.68 | 2.84 | 5.55 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 |
| Revenue Per Share | 0.54 | 0.39 | 0.39 | 0.28 | 0.60 |
| Net Income Per Share | -0.87 | -1.19 | -1.08 | -1.23 | -0.94 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.01 |
| Interest Burden | 1.00 | 1.00 | 0.89 | 0.97 | 1.00 |
| Research & Development to Revenue | 2.12 | 3.42 | 3.15 | 4.26 | 2.10 |
| SG&A to Revenue | 0.67 | 1.04 | 0.97 | 1.21 | 0.48 |
| Stock-Based Compensation to Revenue | 0.42 | 0.69 | 0.52 | 0.57 | 0.21 |
| Income Quality | 1.37 | 1.01 | 1.16 | 1.01 | 1.02 |
Currency in USD

